Clinical Research Directory
Browse clinical research sites, groups, and studies.
Low-Dose Involved-Field Radiotherapy Plus Immunochemotherapy for ESCC
Sponsor: Sichuan University
Summary
The aim of this clinical trial is to evaluate whether low-dose involved-field radiotherapy combined with immunochemotherapy can reduce treatment-related adverse effects, enhance progression-free survival (PFS), and improve overall survival (OS) in patients with locally advanced, unresectable esophageal squamous cell carcinoma. The key questions this study seeks to address are: * Can low-dose involved-field radiotherapy combined with immunochemotherapy reduce treatment-related adverse effects? * Does this combined approach improve PFS and OS in these patients? Participants in the study will: * Undergo an endoscopy at West China Hospital to confirm their diagnosis. * Receive a treatment regimen that includes low-dose radiotherapy at 45.0 Gy in 1.8 Gy per fraction over 25 fractions, alongside immunochemotherapy, with three cycles of chemotherapy administered every 3 weeks. * After completing the full treatment regimen, participants will undergo regular follow-up visits and monitoring by healthcare professionals.
Official title: Low-Dose Involved-Field Radiotherapy Combined with Immunochemotherapy for Locally Advanced, Unresectable Esophageal Squamous Cell Carcinoma: a Prospective, Single-Arm, Phase II Study.
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
41
Start Date
2023-08-24
Completion Date
2025-09-01
Last Updated
2024-12-03
Healthy Volunteers
No
Interventions
low-dose involved-field radiotherapy combined with immunochemotherapy
low-dose involved-field radiotherapy combined with immunochemotherapy
Locations (1)
West China Hospital of Sichuan University
Chengdu, Sichuan, China